Long-Term Nonclinical Pulmonary Safety Assessment of Afrezza, a Novel Insulin Inhalation Powder

136-LB: Effective Treatment of T2D Patients Uncontrolled on Multiple Diabetes Medications by Adding Afrezza Mealtime Ultra-Rapid Insulin

(2019) PHILIP LEVIN et al.   DIABETES

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial

(2011) P. Raskin et al.   DIABETES OBESITY & METABOLISM

Insulin Lung Deposition and Clearance Following Technosphere® Insulin Inhalation Powder Administration

(2011) James P. Cassidy et al.   PHARMACEUTICAL RESEARCH

Growth effects of insulin and insulin analogues

(2011) Juergen Sandow   ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY

A Review of Inhaled Technosphere Insulin

(2010) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

Technosphere® Insulin

(2010) Joshua J. Neumiller et al.   BIODRUGS

Effect of Technosphere Inhaled Insulin on Quality of Life and Treatment Satisfaction

(2010) Mark Peyrot et al.   Diabetes Technology & Therapeutics

Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts

(2010) M. Warnken et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin

(2009) K. Rave et al.   DIABETES OBESITY & METABOLISM

The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes

(2009) Swapnil N. Rajpathak et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS